A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2014 by MedImmune LLC
Sponsor:
Collaborator:
Amplimmune
Information provided by (Responsible Party):
MedImmune LLC
ClinicalTrials.gov Identifier:
NCT02013804
First received: December 12, 2013
Last updated: December 3, 2014
Last verified: December 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2016
  Estimated Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)